Compare Organon & Co. Common Stock (OGN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Recursion Pharmaceuticals Inc trades at $3.65 (market cap $2.02B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| OGN | RXRX | |
|---|---|---|
Market Cap | $3.61B | $2.02B |
Volume | 1,808,049 | 18,610,436 |
Sector | Health | Health |
52-Week High | $13.81 | $6.79 |
52-Week Low | $5.70 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $11.03B | $1.54B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after beating expectations in previous quarters. Financials show significant losses with -961.97% net income margin and $644.76M net loss in 2025, though revenue grew to $74.26M. Recent strategic partnerships with Tempus and Roche highlight AI-driven drug discovery focus.
Outlook remains speculative with high-risk/high-reward profile. The AI drug discovery platform shows promise through partnerships, but profitability challenges and cash burn require careful monitoring. Analyst consensus leans cautious with 40% buy ratings amid substantial operational losses. Key catalysts include pipeline advancements and partnership milestones through 2028.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
